COVID-19 in pediatric kidney transplantation: The Improving Renal Outcomes Collaborative

There are limited data on the impact of COVID-19 in children with a kidney transplant (KT). We conducted a prospective cohort study through the Improving Renal Outcomes Collaborative (IROC) to collect clinical outcome data about COVID-19 in pediatric KT patients. Twenty-two IROC centers that care for 2732 patients submitted testing and outcomes data for 281 patients tested for SARS-CoV-2 by PCR. Testing indications included symptoms and/or potential exposures to COVID-19 (N = 134, 47.7%) and/or testing per hospital policy (N = 154, 54.8%). Overall, 24 (8.5%) patients tested positive, of which 15 (63%) were symptomatic. Of the COVID-19-positive patients, 16 were managed as outpatients, six received non-ICU inpatient care and two were admitted to the ICU. There were no episodes of respiratory failure, allograft loss, or death associated with COVID-19. To estimate incidence, subanalysis was performed for 13 centers that care for 1686 patients that submitted all negative and positive COVID-19 results. Of the 229 tested patients at these 13 centers, 10 (5 asymptomatic) patients tested positive, yielding an overall incidence of 0.6% and an incidence among tested patients of 4.4%. Pediatric KT patients in the United States had a low estimated incidence of COVID-19 disease and excellent short-term outcomes.     

Neoadjuvant combination of pazopanib or axitinib and programmed cell death protein-1-activated dendritic cell-cytokine-induced killer cells immunotherapy may facilitate surgery in patients with renal cell carcinoma

BackgroundRadical/cytoreductive nephrectomy or nephron-sparing surgery may be thought to be not safe or unfeasible in some renal cell carcinoma (RCC) patients in which tumor is locally advanced or highly complicated. Neoadjuvant therapy may reduce the volume of the tumor, thus facilitates surgery. The aim the study is to evaluate the efficacy and safety of neoadjuvant combination of pazopanib or axitinib and PD-1-activated dendritic cell-cytokine-induced killer (PD-1/DC-CIK) cell immunotherapy in those patients.MethodsData from 16 RCC patients who received neoadjuvant pazopanib (Group P, n=9) or axitinib (Group A, n=7) plus PD-1/DC-CIK cells immunotherapy were reviewed retrospectively. A total of 9 participants that were potential candidates for radical/cytoreductive nephrectomy (RN/CN) had locally advanced tumor and 5 participants with partial nephrectomy (PN) absolute indications had highly complicated tumors. The efficacy outcomes were based on volume changes of the primary tumor, lymph nodes, and tumor thrombus in 13 participants with complete computed tomography (CT) imaging. The treatment-related toxicities and surgical complications were also reported.ResultsWith a median of 2.1 months treatment, the overall volume of the tumors decreased by a median of 42.30% [interquartile range (IQR): 19.37–66.78%]. Specifically, the median reduction of tumor volume was 88.77 and 15.50 cm³ in group P and group A, respectively (P=0.014). However, participants in Group P were more likely to experience grade 3 or 4 treatment-related adverse events (AEs) than those in Group A (44.4% vs. 0). Finally, all participants were candidates for appropriate surgery after neoadjuvant therapy (as assessed by the surgeon), and 10 participants accepted surgery, including 5 PN, 4 RN/CN, and 1 lymph node dissection. A solitary participant had Clavien grade IV acute renal failure required dialysis and another had grade II lymphatic leakage.ConclusionsNeoadjuvant combination of pazopanib or axitinib and PD-1/DC-CIK cells immunotherapy was well-tolerated and could effectively reduce the volume of tumors in locally advanced or highly complicated RCC patients.     

妊娠中期腹腔镜拆除极简式宫颈环扎带5例及文献复习

<正>本文报道了5例中孕期在腹腔镜下拆除环扎带的病例,此5例患者均于孕前行“腹腔镜下极简式宫颈环扎术”,在拆除环扎带时的孕周分别是24⁺²、16⁺³、21⁺¹、23⁺⁴、16周。除病例1腹腔镜手术失败中转开腹外,其余4例均顺利完成腹腔镜手术。此4例患者均仅将环扎带剪断,取出环扎带线结,并未拆除环扎带,术后胎儿经阴道顺利娩出。     

经络轨迹的叩击、电阻、电流综合检测实验研究

<正> 应用多种方法对经络的循行路线进行了检测和显示,证明其行程与古典的经络路线基本一致,结果稳定,可重复。但是,显性感传的经络现象在人群中只占25％左右,而人群中大多数是属于隐性感传,应用生物物理学方法已观察到皮肤低电阻点(穴位)循     

小儿废用性骨质疏松与骨折

为提高对废用性骨质疏松与骨折的警惕性,探讨其防治措施,对13 例儿童因 髋关节疾病经手术、石膏固定术后1~9个月,发生废用性骨质疏松和骨折进行了回顾性分析 。结果：13例患儿15个部位发生了废用性骨折,经非手术疗法,配合药物治疗,获骨性愈合 。早期确定废用性骨质疏松的诊断,缩短不必要的肢体固定时间,尽早功能锻练,加强保护 ,避免外伤,配合内科药物疗法对防治本病有重要作用。     

妊娠小鼠子宫GMG细胞中活性蛋白与胚泡植入关系的研究

取孕 1 3～ 1 4d小鼠的子宫腺细胞区 ,经细胞分离和蛋白提取获得颗粒子宫腺细胞 (GMG细胞 )中的活性蛋白。将注入活性蛋白的 1 0只孕 3d小鼠作为实验组 ;对照组 1 0只小鼠给予PBS。注射后 5d取子宫观察胚胎着床情况并计算孕胚数。结果 :实验组有 9只可见胚胎 ,胚胎数为 1 1 2个 ;对照组有 7只可见胚胎 ,胚胎数为 87个。提示 :GMG细胞中的活性蛋白对胚泡着床可能有一定促进作用